Q32 Bio Inc. financial data

Symbol
QTTB on Nasdaq
Industry
Pharmaceutical Preparations
Location
830 Winter Street, Waltham, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
Homology Medicines, Inc. (to 3/22/2024)
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 430 % -43.5%
Debt-to-equity -2.93K % -2857%
Return On Equity 3.74K % +2238%
Return On Assets -100 % -167%
Operating Margin -8.77K % -111%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 12.1M shares -79.1%
Common Stock, Shares, Outstanding 12M shares -79.2%
Entity Public Float 45.8M USD -50.4%
Common Stock, Value, Issued 2K USD -66.7%
Weighted Average Number of Shares Outstanding, Basic 12M shares +3339%
Weighted Average Number of Shares Outstanding, Diluted 12M shares +3339%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD -100%
Revenue from Contract with Customer, Excluding Assessed Tax 1.16M USD -64%
Research and Development Expense 69.3M USD +0.58%
General and Administrative Expense 35.9M USD +72.3%
Operating Income (Loss) -120M USD -45.8%
Nonoperating Income (Expense) 2.39M USD +62.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -87.1M USD -7369%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -116M USD -44.1%
Earnings Per Share, Basic 34.2 USD/shares +91.5%
Earnings Per Share, Diluted 26.8 USD/shares +91.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 97.7M USD +387%
Other Assets, Current 51K USD
Assets, Current 112M USD -15%
Property, Plant and Equipment, Net 1.55M USD +83.8%
Operating Lease, Right-of-Use Asset 6.02M USD -69.7%
Other Assets, Noncurrent 1.1M USD
Assets 124M USD -26.7%
Accounts Payable, Current 2.48M USD -26.8%
Employee-related Liabilities, Current 4.08M USD +13.1%
Accrued Liabilities, Current 11M USD
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 17.2M USD -25%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 5.95M USD -78%
Other Liabilities, Noncurrent 55M USD
Liabilities 90.7M USD +81.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1K USD +98.9%
Retained Earnings (Accumulated Deficit) -203M USD +58.8%
Stockholders' Equity Attributable to Parent 33.5M USD
Liabilities and Equity 124M USD -26.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -14.6M USD -16.4%
Net Cash Provided by (Used in) Financing Activities 99.3M USD +662207%
Net Cash Provided by (Used in) Investing Activities 168M USD
Common Stock, Shares Authorized 400M shares +100%
Common Stock, Shares, Issued 12M shares -79.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 5.47M USD -96%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 98.3M USD +282%
Deferred Tax Assets, Valuation Allowance 221M USD +23.2%
Deferred Tax Assets, Gross 222M USD +19.3%
Operating Lease, Liability 7.3M USD -74.6%
Depreciation 574K USD -46.5%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -116M USD -43%
Lessee, Operating Lease, Liability, to be Paid 9.41M USD -77.9%
Property, Plant and Equipment, Gross 2.76M USD -62.9%
Operating Lease, Liability, Current 1.35M USD -20.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.06M USD -76.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.29M USD -42.5%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.11M USD -84.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.09M USD -76.8%
Deferred Tax Assets, Operating Loss Carryforwards 88.6M USD +15.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.12M USD -76.9%
Additional Paid in Capital 237M USD -61.4%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 8.47M USD +31%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%